These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 38573492)

  • 1. SNHG4-mediated PTEN destabilization confers oxaliplatin resistance in colorectal cancer cells by inhibiting ferroptosis.
    Li SQ; Xu WT; Yin YX; Wei HT; Li KZ; Xie MZ; Lv F; Xie LY; Hu BL
    Apoptosis; 2024 Jun; 29(5-6):835-848. PubMed ID: 38573492
    [TBL] [Abstract][Full Text] [Related]  

  • 2. lncRNA SNHG4 inhibits ferroptosis by orchestrating miR-150-5p/c-Myb axis in colorectal cancer.
    Li SQ; Lv F; Xu WT; Yin YX; Wei HT; Li KZ; Hu BL
    Int J Biol Macromol; 2024 May; 268(Pt 2):131961. PubMed ID: 38692535
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fusobacterium nucleatum induces oxaliplatin resistance by inhibiting ferroptosis through E-cadherin/β-catenin/GPX4 axis in colorectal cancer.
    Li B; Wei Z; Wang Z; Xu F; Yang J; Lin B; Chen Y; Wenren H; Wu L; Guo X; Liu Y; Wei Y
    Free Radic Biol Med; 2024 Aug; 220():125-138. PubMed ID: 38657754
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exosome-transmitted miR-128-3p increase chemosensitivity of oxaliplatin-resistant colorectal cancer.
    Liu T; Zhang X; Du L; Wang Y; Liu X; Tian H; Wang L; Li P; Zhao Y; Duan W; Xie Y; Sun Z; Wang C
    Mol Cancer; 2019 Mar; 18(1):43. PubMed ID: 30890168
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ketogenesis attenuated KLF5 disrupts iron homeostasis via LIF to confer oxaliplatin vulnerability in colorectal cancer.
    Jiang H; Zeng Y; Jiang X; Xu X; Zhao L; Yuan X; Xu J; Zhao M; Wu F; Li G
    Biochim Biophys Acta Mol Basis Dis; 2024 Aug; 1870(6):167210. PubMed ID: 38704001
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Suppressing the KIF20A/NUAK1/Nrf2/GPX4 signaling pathway induces ferroptosis and enhances the sensitivity of colorectal cancer to oxaliplatin.
    Yang C; Zhang Y; Lin S; Liu Y; Li W
    Aging (Albany NY); 2021 Mar; 13(10):13515-13534. PubMed ID: 33819186
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of miR-19a partially reversed the resistance of colorectal cancer to oxaliplatin via PTEN/PI3K/AKT pathway.
    Zhang Y; Liu X; Zhang J; Xu Y; Shao J; Hu Y; Shu P; Cheng H
    Aging (Albany NY); 2020 Mar; 12(7):5640-5650. PubMed ID: 32209726
    [TBL] [Abstract][Full Text] [Related]  

  • 8. lncRNA SNHG4 modulates colorectal cancer cell cycle and cell proliferation through regulating miR-590-3p/CDK1 axis.
    Zhou Z; Tan F; Pei Q; Li C; Zhou Y; Li Y; Pei H
    Aging (Albany NY); 2021 Mar; 13(7):9838-9858. PubMed ID: 33744866
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The c-Myc/miR-27b-3p/ATG10 regulatory axis regulates chemoresistance in colorectal cancer.
    Sun W; Li J; Zhou L; Han J; Liu R; Zhang H; Ning T; Gao Z; Liu B; Chen X; Ba Y
    Theranostics; 2020; 10(5):1981-1996. PubMed ID: 32104496
    [TBL] [Abstract][Full Text] [Related]  

  • 10. LINC00982-encoded protein PRDM16-DT regulates
    Hu HF; Han L; Fu JY; He X; Tan JF; Chen QP; Han JR; He QY
    Theranostics; 2024; 14(8):3317-3338. PubMed ID: 38855188
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overexpression of MEG3 sensitizes colorectal cancer cells to oxaliplatin through regulation of miR-141/PDCD4 axis.
    Wang H; Li H; Zhang L; Yang D
    Biomed Pharmacother; 2018 Oct; 106():1607-1615. PubMed ID: 30119236
    [TBL] [Abstract][Full Text] [Related]  

  • 12. circHIPK3 promotes oxaliplatin-resistance in colorectal cancer through autophagy by sponging miR-637.
    Zhang Y; Li C; Liu X; Wang Y; Zhao R; Yang Y; Zheng X; Zhang Y; Zhang X
    EBioMedicine; 2019 Oct; 48():277-288. PubMed ID: 31631038
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Elevating H3K27me3 level sensitizes colorectal cancer to oxaliplatin.
    Wang Q; Chen X; Jiang Y; Liu S; Liu H; Sun X; Zhang H; Liu Z; Tao Y; Li C; Hu Y; Liu D; Ye D; Liu Y; Wang M; Zhang X
    J Mol Cell Biol; 2020 Feb; 12(2):125-137. PubMed ID: 31065671
    [TBL] [Abstract][Full Text] [Related]  

  • 14. LncRNA CACS15 contributes to oxaliplatin resistance in colorectal cancer by positively regulating ABCC1 through sponging miR-145.
    Gao R; Fang C; Xu J; Tan H; Li P; Ma L
    Arch Biochem Biophys; 2019 Mar; 663():183-191. PubMed ID: 30639170
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long non-coding RNA SNHG4 enhances RNF14 mRNA stability to promote the progression of colorectal cancer by recruiting TAF15 protein.
    Lv L; Huang B; Yi L; Zhang L
    Apoptosis; 2023 Apr; 28(3-4):414-431. PubMed ID: 36482019
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metabolic targeting of HIF-1α potentiates the therapeutic efficacy of oxaliplatin in colorectal cancer.
    Wei TT; Lin YT; Tang SP; Luo CK; Tsai CT; Shun CT; Chen CC
    Oncogene; 2020 Jan; 39(2):414-427. PubMed ID: 31477841
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Downregulation of AC092894.1 promotes oxaliplatin resistance in colorectal cancer via the USP3/AR/RASGRP3 axis.
    Zheng Z; Wu M; Li H; Xu W; Yang M; Pan K; Ni Y; Jiang T; Zheng H; Jin X; Zhang Y; Ding L; Fu J
    BMC Med; 2023 Apr; 21(1):132. PubMed ID: 37013584
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NFYB-induced high expression of E2F1 contributes to oxaliplatin resistance in colorectal cancer via the enhancement of CHK1 signaling.
    Fang Z; Gong C; Yu S; Zhou W; Hassan W; Li H; Wang X; Hu Y; Gu K; Chen X; Hong B; Bao Y; Chen X; Zhang X; Liu H
    Cancer Lett; 2018 Feb; 415():58-72. PubMed ID: 29203250
    [TBL] [Abstract][Full Text] [Related]  

  • 19. EVs delivery of miR-1915-3p improves the chemotherapeutic efficacy of oxaliplatin in colorectal cancer.
    Xiao Z; Liu Y; Li Q; Liu Q; Liu Y; Luo Y; Wei S
    Cancer Chemother Pharmacol; 2021 Dec; 88(6):1021-1031. PubMed ID: 34599680
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long noncoding RNA CCAL transferred from fibroblasts by exosomes promotes chemoresistance of colorectal cancer cells.
    Deng X; Ruan H; Zhang X; Xu X; Zhu Y; Peng H; Zhang X; Kong F; Guan M
    Int J Cancer; 2020 Mar; 146(6):1700-1716. PubMed ID: 31381140
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.